AIM ImmunoTech, Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for myriad indications.
IR Website: aimimmuno.com
Headquarters: Ocala, FL
TALK TO MANAGEMENT
AIM ImmunoTech Inc. is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Stock Chart (Intraday)
Stock Chart (Historical)
Ampligen® - A Wide Variety of Potential Applications
Alferon N Injection®
Strong Cash Position & Poised for Commercialization
Video: Virtual Investor Spotlight Series
Risks & Disclosures
The AIM ImmunoTech's management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the AIM ImmunoTech story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.